NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update Feb 27, 2026 04:03PM
NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis Dec 19, 2025 04:04PM
NurExone Secures over C$3.18 Million Through Accelerated Warrant Exercises Nov 12, 2025 04:02PM
NurExone Accepted into ARMI’s BioFab Startup Lab Strengthening U.S Position in Regenerative Manufacturing Nov 3, 2025 04:04PM
NurExone Receives U.S. Patent Allowance for Exosome Manufacturing, Strengthening Supply Chain Readiness Sep 8, 2025 04:30PM


Aug 20, 2025 04:03PM NurExone Biologic Announces Preclinical Evidence of Structural Repair in Injured Spinal Cord Tissue following ExoPTEN Treatment
Jul 25, 2025 04:02PM NurExone Biologic Finalist in Falling Walls Venture 2025 Global Platform Showcasing The World’s Most Promising Science-Based Start-Ups
May 8, 2025 04:04PM NurExone Advances Vision Restoration Strategy with Preclinical Data Presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2025
May 2, 2025 04:05PM NurExone Expands European Engagement with Investor Events in Germany and Switzerland
Jan 21, 2025 04:20PM NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director
Dec 3, 2024 07:00AM Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now
Oct 31, 2024 07:00AM NRx Pharmaceuticals added to Emerging Growth Conference 76 on October 31 and Update to Schedule
Oct 30, 2024 07:00AM Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now
Oct 29, 2024 07:00AM Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now
Aug 28, 2024 08:34AM NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Aug 9, 2024 04:04PM NurExone's ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study
Jul 17, 2024 07:00AM Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now
Jun 21, 2024 04:04PM On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development
Jun 4, 2024 04:40PM NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders
May 29, 2024 08:35AM NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials
May 17, 2024 04:04PM NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations
Apr 2, 2024 08:31AM NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update
Mar 15, 2024 04:05PM NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence
Mar 1, 2024 04:04PM NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit
Feb 20, 2024 04:05PM NurExone’s Intellectual Property Portfolio Expands
Feb 2, 2024 04:05PM Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant
Jan 17, 2024 08:34AM NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar Healthcare Market
Jan 5, 2024 08:30AM NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million
Nov 29, 2023 08:30AM NurExone Biologic Extends Spinal Cord Injury Therapy Portfolio With New RNA Sequences Promoting Healing and Regeneration
Nov 24, 2023 08:30AM NurExone Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Oct 11, 2023 08:30AM NurExone Secures Eureka Grant for Collaborative Partnership to Expand to Chronic Spinal Cord Injury Therapy
Sep 28, 2023 08:30AM NurExone Appoints Dr. Reuter Investor Relations in Europe
Sep 13, 2023 08:30AM NurExone Moves Forward Towards Human Clinical Trials, Completes Pre-IND Meeting with the FDA for Proprietary ExoPTEN Drug
Aug 28, 2023 08:30AM NurExone Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Jul 20, 2023 08:15AM NurExone Biologic Announces Advancements in Extracellular Vesicles Functionality with Enhanced Potency and Cellular Uptake for potentially better drug delivery
Jun 22, 2023 08:00AM Regeneration and Reinnervation of Spinal Cord in Rats Treated with NurExone's Intranasal ExoPTEN
Jun 1, 2023 08:00AM NurExone and Particle Metrix Announce Collaboration in Extracellular Vesicles Analysis Using State-of-the-art Analytic Device
May 24, 2023 07:19AM NurExone Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 16, 2023 08:30AM NurExone Granted U.S. Patent for Technology and Drug Composition of Exo-PTEN, Designed for Treating Acute Spinal Cord Injuries
Mar 30, 2023 08:40AM NurExone Announces Q4 and Full-year 2022 Financial Results and Provides Company Update, Highlighting 143.9% Scientific Research Investment Growth
Mar 20, 2023 07:58AM NurExone Biologic Reports Additional Positive Preclinical Trial Outcomes with ExoPTEN: 75% of Paralyzed Rats Show Recovery after Acute Spinal Cord Injury Study
Feb 17, 2023 08:00AM NurExone Announces Interim Positive Results of Internal Preclinical Study of Proprietary ExoPTEN Drug
Jan 13, 2023 03:00PM United States Patent Office Allows Patent to Exosome Biomedical Company Nurexone
Feb 12, 2014 10:00AM NephroGenex [NRX] to Ring The NASDAQ Stock Market Opening Bell in Celebration of Recent IPO
Feb 11, 2014 12:23PM NASDAQ Welcomes NephroGenex (NASDAQ:NRX) to The NASDAQ Stock Market